Asked by Fierce if he’d consider returning to the FDA, Pazdur said he wouldn’t serve again under the Trump administration “for obvious reasons.”
The acquisition helps diversify UCB’s small molecule-centric arsenal of seizure treatments with a potentially one-off therapy in early testing for a hard-to-treat form of a common...
Despite its small size—it could sit in the palm of your hand—the zebra finch is a remarkable learner. A songbird native to Australia, it’s renowned for...
A group of scientists have developed a targeted delivery platform that can induce anti-inflammatory cytokine expression in mouse lungs, which helps restrict tissue damage from respiratory...
Revolution Medicines announced a stunning survival benefit for its experimental drug in a Phase 3 pancreatic cancer study this week. Patients with advanced pancreatic adenocarcinoma who...
New CDC pick Schwartz is praised by public health pros
Modern biology is accelerating at an unprecedented pace, and with it comes increasing complexity. As a result, researchers are shifting toward more patient reflective models, uncovering...
REGISTER NOW Broadcast Date: Wednesday, April 29, 2026 Time: 08:00 PDT, 11:00 EDT, 15:00 GMT Next-generation sequencing (NGS) has never been cheaper or more accessible. In turn, spatial...
On Friday, Kailera Therapeutics raised a record-setting $625 million through an IPO on the Nasdaq. Founded with backing from Bain Capital Life Sciences, and a pipeline...
#AACR26 preview: Revolution Medicines, the RAS bonanza and China ADC standouts